Área salud
Multiple sclerosis
Área salud
Impact of the COVID-19 pandemic on the physical activity habits of people with multiple sclerosis in Spain
Background According to the literature, patients with multiple sclerosis (MS) are less active and show higher levels of sedentary behaviour than the general population of the same age range. This study aims to explore the […]
Área salud
Multiple sclerosis: A descriptive series
Introduction Multiple sclerosis (MS) is a chronic multifocal inflammatory demyelinating disease that progresses with neurodegeneration and is associated with a high risk of disability. Objectives We describe a series of patients diagnosed with MS in […]
Área salud
Risk of Skin Cancer Associated with Disease-Modifying Therapies in Multiple Sclerosis: A Comprehensive Evidence Review
The use of disease-modifying therapies (DMT) has led to a paradigm shift in the management of multiple sclerosis. A comprehensive narrative review was conducted through an extensive literature search including Medline and Google Scholar to […]
Área salud
Relationship between inflammation and oxidative stress and its effect on multiple sclerosis
Introduction This paper highlights the relationship of inflammation and oxidative stress as damage mechanisms of Multiple Sclerosis (MS), considered an inflammatory and autoimmune disease. Development The oxidative stress concept has been defined by an imbalance […]
Área salud
Cognitive rehabilitation program in patients with multiple sclerosis: A pilot study
Introduction In recent years, there has been an increase of studies dedicated to cognitive rehabilitation in patients with multiple sclerosis (MS); however, few of these analyze the impact on such variables as cognitive reserve. The […]
Área salud
Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study
Introduction and objective Teriflunomide is an oral immunomodulatory agent approved for the treatment of relapsing–remitting multiple sclerosis (RRMS). We examined teriflunomide outcomes in patients with RRMS under clinical practice conditions in Spain. Material and methods […]
Área salud
Sleep disorders in patients with multiple sclerosis in Spain
Objective This study assesses the presence of sleep disturbances and their relationship with clinical and demographic variables in patients with MS, with a view to establishing correlations between the different variables and the frequency of […]
Área salud
Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab
Late-onset neutropaenia is defined as an absolute neutrophil count of 4 weeks after the last dose of rituximab, in the absence of other identifiable causes. Late-onset neutropaenia is a rare adverse reaction to rituximab (observed […]
Área salud
Monitoring response to disease-modifying treatment in multiple sclerosis
Background Standard criteria for defining suboptimal response to disease-modifying treatment (DMT) in patients with multiple sclerosis (MS) are lacking. Decision-making on how and when DMTs should be switched is challenging. The objective of the study […]